MUMBAI, SEPTEMBER 19, 2006 – Bilcare Ltd, India’s leading pharma major in the drug discovery to market value chain, has acquired DHP Limited, a UK-based Clinical Trials Services provider.

The 100% paid-up equity of DHP has been acquired through Bilcare (UK) Limited, a fully-owned subsidiary of Bilcare. DHP had service revenue of US$ 3 million for the year ended March 31, 2006.

Commenting on this important acquisition in UK, Mr. Mohan Bhandari, the Chairman and Managing Director of Bilcare Limited said, “Bilcare has been successful in living up to its commitment of providing a truly world-wide operations network to the global pharmaceutical sector and partner with them in enhancing their speed to market by best in class local management of their global clinical trials.”

With this acquisition, Bilcare completes a full circle in establishing global clinical trial services. With the intent of evolving itself into a “life-Sciences Knowledge Partner Matrix” – (KPM); Bilcare channelised its research and innovations competencies in meeting its first phase objective of establishing a truly global capability in one of the most critical activities in the pharma value chain – Clinical Trials Services (CTS).

DHP Limited are UK / EU specialists to the global pharmaceutical sector since 1988 in the manufacture, importation, storage and distribution of phase I-IV Investigational Medicinal Products and named patient / compassionate use medicinal products. This includes a full range of QP and other services to support the Investigational Medicinal Product lifecycle from design through reconciliation and destruction, based in Powys, UK. DHP's objective with each client is to provide a GMP/GCP compliant service, which combines an uncompromising approach to QA with recognition that the sponsor’s needs are for a flexible, prompt and reliable servicing of requirements, within tight time limits. The clientele of DHP Limited included multinational pharmaceutical companies, biotech companies, leading Contract Research Organisations, publicly (MRC) funded clinical research teams, NHS trusts and hospitals as well as individual professionals in the public and academic sectors. DHP Limited works in strict accordance with the EU Clinical Trials Directive and other relevant regulation. DHP Limited was last inspected by the MHRA with respect to its MA-IMP license in January 2006.

Bilcare’s focused ambition to be the leader in Clinical Trial Services was initiated with the establishment of a state-of-the-art CTS facility in India in early 2005. The aim was to cater to global pharmaceutical customers, specifically the European based companies. It almost simultaneously expanded its global reach through the acquisition of an established clinical trials business in the USA in the Quarter III of 2005. The USA acquisition was welcomed by the pharma industry leading to Bilcare’s getting recognition as their value partner. Bilcare delighted the expectations of the pharma industry by announcing its serious intent of establishing similar capabilities in Singapore and the European Union to make Bilcare one of the few players with global servicing capability. While Bilcare initiated its Singapore CTS operations by integrating it into its materials and research facilities in Singapore, which also has been conferred with the prestigious “Pioneer Status” by the Government of Singapore, the recent UK acquisition has become the most strategic component of Bilcare’s conclusive step towards converting Bilcare’s Clinical Trail Services into a truly global activity.

About Bilcare Limited

Bilcare Limited is a unique research driven organisation with a clear focus, to be the global leader in providing a true value partnership to the worldwide life sciences sector through its novel range of products and services and address the dynamic and challenging needs of the pharma value chain from discovery to market. Bilcare has a well-managed blend of knowledge, human assets and research initiatives and research and manufacturing facilities in India, USA and Singapore. Bilcare with its services encompassing Clinical trials services, packaging research, design and development and formulation and Analytical services and its unique comprehensive range of packaging materials is being recognized as the leader in providing value solutions supporting the complete value chain of the pharmaceutical sector.

Bilcare continues to march ahead in with continual expansion initiatives of its existing operations and establishing new operations in the other key markets of the world to ensure the expertise and service reaches its customer and meet their needs in any part of the world.